Severine Cathelin

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors.

Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors.

Journal: Blood neoplasia
Published: July 28, 2025

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS.

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS.

Journal: Blood
Published: July 14, 2025

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS.

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS.

Journal: Blood
Published: July 14, 2025

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

Journal: The Lancet. Haematology
Published: May 23, 2025

TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.

TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.

Journal: Nature communications
Published: March 22, 2024

Metformin reduces the clonal fitness of Dnmt3a R878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state.

Metformin reduces the clonal fitness of Dnmt3a R878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state.

Journal: Research square
Published: February 26, 2024

Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs.

Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs.

Journal: Nature
Published: January 18, 2024

Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.

Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.

Journal: Cancer research
Published: April 19, 2022

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.

Journal: PLoS computational biology
Published: June 16, 2021

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.

Journal: Leukemia
Published: March 29, 2021

Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis.

Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis.

Journal: Cell stem cell
Published: September 28, 2020

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.

Journal: Science translational medicine
Published: March 11, 2019
Showing 1-12 of 12

Last Updated: 09/26/2026